kabutan

Eisai Co., Ltd.(4523) Summary

4523
TSE Prime
Eisai Co., Ltd.
4,829
JPY
+32
(+0.67%)
Mar 13, 3:30 pm JST
30.29
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
4,808
Mar 13, 9:40 pm JST
Summary Chart Historical News Financial Result
PER
32.8
PBR
1.53
Yield
3.31%
Margin Trading Ratio
19.70
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
4,732 JPY 29.71 USD
Previous Close Mar 12
4,797 JPY 30.17 USD
High Mar 13, 12:48 pm
4,873 JPY 30.58 USD
Low Mar 13, 9:00 am
4,731 JPY 29.71 USD
Volume
1,263,200
Trading Value
6.07B JPY 0.04B USD
VWAP
4805.39 JPY 30.15 USD
Minimum Trading Value
482,900 JPY 3,029 USD
Market Cap
1.41T JPY 8.86B USD
Number of Trades
2,802
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
High
1-Year Average
3,733
1-Year High May 15, 2025
11,589
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 75,900 937,100 12.35
Feb 27, 2026 97,300 921,600 9.47
Feb 20, 2026 100,400 1,009,900 10.06
Feb 13, 2026 107,600 1,067,800 9.92
Feb 6, 2026 48,900 1,972,400 40.34
Company Profile
Eisai Co., Ltd. is a major pharmaceutical company with strengths in neurology and gastrointestinal oncology. The company has expanded into the field of dementia treatments.
Sector
Pharmaceuticals
Eisai's pharmaceutical business accounts for 90% of its sales, encompassing research and development, manufacturing, and sales of both prescription and over-the-counter medicines. The company has a strong global presence with a high overseas sales ratio. Outside Japan, Eisai operates in North America, China, EMEA (Europe, Middle East, Africa, Russia, and Oceania), and Asia-Latin America (South Korea, Taiwan, India, ASEAN, and Latin America). Internationally, Eisai conducts business through its subsidiaries in various regions. In Japan, the company collaborates with group companies such as KAN Research Institute and EA Pharma to advance its operations. In the United States, Eisai markets an Alzheimer's disease treatment that gained attention as the world's first medication to demonstrate a reduction in early clinical symptom progression during clinical trials. Leveraging its global research and development infrastructure and sales network, Eisai aims to provide pharmaceuticals that meet the needs of patients worldwide.